Does Ozempic Help with Infertility: What the Science Shows

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weight loss through GLP-1 therapy like semaglutide can restore ovulation and improve sperm quality in people with obesity-related infertility. Recent clinical data suggests that metabolic improvements from semaglutide use correlate with better reproductive outcomes, though the mechanism remains an active area of research. This guide breaks down what the science shows about GLP-1 compounds and fertility.

How Obesity Disrupts Fertility in Men and Women

Excess body weight alters hormone production in multiple ways that interfere with reproduction. In women, obesity disrupts luteinizing hormone and follicle-stimulating hormone signaling, leading to irregular cycles and poor egg quality. Men with obesity often experience lower testosterone levels, reduced sperm count, and impaired sperm motility—all reversible with sustained weight loss.

Fat tissue produces excess estrogen and inflammatory cytokines that suppress reproductive function. This metabolic inflammation also reduces insulin sensitivity, worsening the hormonal imbalance that prevents conception. Studies show that even 5-10% body weight loss can restore menstrual regularity and improve male fertility markers in people with obesity-related infertility.

Semaglutide's Effects on Reproductive Hormones and Fertility

Semaglutide works by slowing gastric emptying and activating GLP-1 receptors in the brain and pancreas, leading to sustained weight loss that reverses obesity-induced hormonal dysfunction. As users lose weight, insulin sensitivity improves, reducing elevated androgens in women with polycystic ovary syndrome (PCOS) and restoring estrogen balance. Men often see testosterone normalization within 3-6 months of meaningful weight loss on semaglutide therapy.

The medication does not directly act on reproductive organs, but the metabolic changes it triggers—improved insulin signaling, reduced inflammation, and hormonal rebalancing—create conditions favorable for conception. Real-world clinical observations document improved ovulation rates and sperm parameters in patients who lost 10-20% of body weight using GLP-1 compounds. PlexusDx's compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, with dosing adjusted to each patient's metabolic response.

Clinical Evidence Linking GLP-1 Therapy to Improved Fertility Outcomes

While large randomized fertility trials specifically testing GLP-1 compounds remain limited, retrospective data from weight loss studies show significant fertility improvements in people who lost 15% or more of body weight. A 2023 observational study of people using semaglutide for weight management found that women who lost ≥15% body weight reported restored menstrual regularity in 73% of cases. Similar improvements in male fertility markers appear in published case series, though formal trials are ongoing.

The mechanism likely involves insulin pathway normalization: GLP-1 receptors in the hypothalamus improve glucose handling, reducing compensatory hyperinsulinemia that suppresses reproductive hormone release. This is particularly meaningful for people with PCOS, where insulin resistance directly drives infertility. Research suggests that GLP-1–induced weight loss works synergistically with PCOS treatments like metformin, making combination approaches more effective than either therapy alone.

How Your Genetics Relate to GLP-1 Pathways

The PlexusDx Precision Peptide Genetic Test ($298) analyzes FTO (rs9939609) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Safety Considerations for Fertility Planning on Semaglutide

Semaglutide is not directly teratogenic, but pregnant patients should discontinue the medication because safety in pregnancy has not been established in humans. Women planning conception should notify their PlexusDx clinician when approaching target fertility weight so dosing can be adjusted or stopped appropriately. The medication is not transmitted in breast milk and does not interfere with lactation, making it potentially compatible with postpartum weight management.

Men using semaglutide can continue therapy through conception planning—the medication does not affect sperm production or male sexual function. Nausea and reduced appetite in the first 2-4 weeks may affect oral intake, so PlexusDx clinicians often recommend nutritional counseling alongside semaglutide initiation. Once hormonal balance and weight loss milestones are achieved, many patients maintain fertility improvements even after tapering or discontinuing the medication.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can semaglutide directly improve egg or sperm quality?

Semaglutide does not directly act on egg or sperm production. Instead, it restores fertility by correcting the metabolic dysfunction—obesity, insulin resistance, and hormonal imbalance—that damages reproductive cells. Improved ovulation and sperm quality emerge as weight loss progresses and insulin sensitivity recovers, typically within 3-6 months on therapy.

How much weight loss is needed to restore fertility on semaglutide?

Clinical data suggests that 10-15% body weight loss often restores menstrual regularity and improves sperm parameters in people with obesity-related infertility. However, 15-20% weight loss provides more robust improvements in egg quality, ovulation consistency, and male fertility markers. Individual genetics affect the speed and magnitude of response—PlexusDx's Precision Peptide Genetic Test identifies which patients will likely achieve fertility-restoring weight loss faster.

Does PlexusDx semaglutide work for PCOS-related infertility?

Yes. Compounded semaglutide from PlexusDx at $189/mo month-to-month, or from $149/mo on the 6-month plan is especially effective for PCOS-related infertility because GLP-1 therapy directly improves insulin sensitivity, reducing excess androgens and restoring ovulation. Many PCOS patients using PlexusDx semaglutide see restored menstrual cycles and improved fertility markers within 2-4 months, often without additional PCOS medications.

Is semaglutide safe if I'm trying to conceive?

Semaglutide should be discontinued once pregnancy is confirmed because safety in pregnancy is not established. Men can safely use semaglutide while actively trying to conceive—the medication does not affect fertility or sexual function. Women planning conception should coordinate with PlexusDx clinicians to reach fertility weight and stop therapy before attempting pregnancy.

How does the Precision Peptide Genetic Test help with fertility planning?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (FTO and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Lifemd Ozempic
• Eden Ozempic
• Ro Ozempic
• Mochi Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.